文献速递慢性肾脏病

多病共存与基于肌酐和胱抑素C的eGFR不一致性的关联

Association between multimorbidity and discordance between creatinine- and cystatin C-based eGFR.
PubMed 文献 · Nephrol Dial Transplant · 2026-10-10

在超过40万英国生物银行参与者中,使用欧洲肾脏功能联盟方程计算eGFRcr和eGFRcys,发现多病共存(≥2种长期状况)占33%,且与eGFR不一致性显著相关;四种及以上长期状况者出现大幅负向eGFR差异的调整比值比为4.64(95%CI 4.13-5.21)。建议多病共存个体同时检测胱抑素C以优化肾功能评估和风险分层。

要点

  • 多病共存(≥2种长期状况)与eGFRcr和eGFRcys之间的不一致性增加相关。
  • 四种及以上长期状况者出现大幅负向eGFR差异的风险是无长期状况者的4倍以上。
  • 多病共存个体应考虑同时检测胱抑素C以细化肾功能评估和风险分层。

核心结论

  • 基于肌酐和基于胱抑素C的eGFR之间的不一致性随着多病共存程度增加而显著增大。

研究设计与样本

  • 在超过40万英国生物银行参与者中计算eGFRcr和eGFRcys,并统计自报长期状况,分析多病共存与eGFR不一致性的关联。

主要发现

  • 多病共存(≥2种长期状况)占整体队列的33%,占大幅负向eGFR差异者的63%。
  • 当基于eGFRcr的CKD分期改用eGFRcys重新评估时,15%的队列被重新分类为更晚期的CKD阶段,且重新分类频率随长期状况数量增加而逐渐升高。
  • 四种及以上任何类型长期状况者出现大幅负向eGFR差异的调整比值比为4.64(95%CI 4.13-5.21),参照组为无长期状况者。

关键数值与推荐

  • 大幅负向eGFR差异定义为eGFRcys比eGFRcr低超过30%,即([eGFRcys - eGFRcr]/eGFRcr) <-30%。
  • 多病共存定义为两种或以上任何类型的长期状况。

临床怎么用

  • 在多病共存个体中,应考虑同时检测胱抑素C(与肌酐一起)以优化肾功能评估和风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: Large differences between glomerular filtration rate estimated with creatinine and cystatin C-termed eGFR discordance-have important implications for health. Several demographic factors and individual long-term conditions (LTCs) are associated with eGFR discordance. We hypothesise that the presence of multiple LTCs i.e. multimorbidity is likely to be associated with eGFR discordance. METHODS: Differences between creatinine-based and cystatin C-based eGFR (eGFRcr and eGFRcys, respectively) using European Kidney Function Consortium equations were calculated in over 400 000 UK Biobank participants. Large negative eGFR difference was defined as an eGFRcys more than 30% lower than eGFRcr i.e. ([eGFRcys - eGFRcr]/eGFRcr) <-30%. Self-reported LTCs were counted and analysed overall and by type of multimorbidity (cardiometabolic, non-cardiometabolic, mixed mental and physical). Proportions of participants with large negative eGFR differences were cross-tabulated at different chronic kidney disease (CKD) stages and according to number of LTCs. The association between number of LTCs and eGFR discordance was assessed in logistic regression models adjusted for age, sex, body mass index, smoking status and thyroid disease. RESULTS: Multimorbidity (two or more LTCs of any type) was observed in 33% of the overall cohort and 63% of those with large negative eGFR differences. When CKD stage was assigned based on eGFRcr and then reassigned using eGFRcys, 15% of the cohort were reclassified to a more advanced CKD stage with frequency of reclassification increasing progressively with increasing counts of LTCs. Individuals with four or more LTCs of any type were more than four-fold more likely to have a large negative eGFR difference (adjusted odds ratio 4.64, 95% confidence interval 4.13-5.21) compared to individuals with no LTCs. CONCLUSION: Discordance between creatinine-based and cystatin C-based eGFR increased substantially with multimorbidity. Cystatin C testing should be considered (alongside creatinine) in individuals with multimorbidity to refine estimation of kidney function and risk stratification.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Mayne KJ, Walker H, Sullivan MK, et al. Association between multimorbidity and discordance between creatinine- and cystatin C-based eGFR. Nephrol Dial Transplant. 2026. PMID: 42858001. doi:10.1093/ndt/gfag232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。